This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Steris’ Expansion Gamble: How Heavy Investment in New Technologies Could Pressure Profitability
Steris (STE) has disclosed a new risk, in the Innovation / R&D category.
Claim 55% Off TipRanks
- Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
- Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
Steris faces the risk that substantial cash devoted to new technologies, infrastructure, and manufacturing expansions may not generate the anticipated returns. If these investments underperform, the company’s profitability could be materially impacted and management focus may be pulled away from more proven, profitable operations.
The average STE stock price target is $284.50, implying 33.74% upside potential.
To learn more about Steris’ risk factors, click here.
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
